Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679655 | 0.94 | MMP2 (0.51) | MAOBALDH1A1MMP2HPGDHRH3 | |
| SCHEMBL11784760 | 0.86 | MAOB (0.57) | MAOBALDH1A1MAPTCYP2A6MMP2 | |
| SCHEMBL3589633 | 0.83 | NQO1 (0.50) | MAOBMAPTMMP2CA1CA2 | |
| SCHEMBL13170580 | 0.82 | APP (0.48) | MMP2MMP3 | |
| SCHEMBL18301590 | 0.81 | MAOB (0.48) | MAOBALDH1A1MAPTMAOACYP2A6 | |
| SCHEMBL4867346 | 0.81 | MAPT (0.61) | MAOBALDH1A1MAPTMAOAMMP2 | |
| SCHEMBL17856189 | 0.80 | MMP2 (0.58) | MAOBALDH1A1MMP2HPGDHRH3 | |
| SCHEMBL4258655 | 0.80 | ESR1 (0.49) | MAOBMAPTMAOARAB9A | |
| SCHEMBL4258651 | 0.80 | ESR1 (0.49) | MAOBMAPTMAOARAB9A | |
| SCHEMBL6132301 | 0.79 | ALDH1A1 (0.54) | MAOBALDH1A1MAPTMMP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112592352-A | Polysubstituted benzothienopyridine compound and preparation method thereof | 华南理工大学 | 2021-04-02 | — | — | CN | disclosed |
| EP-1905769-B1 | HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2017-03-29 | — | — | EP | disclosed |
| EP-1810969-B1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | MSD KK (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130184462-A1 | METHOD FOR PREDICTING AND MODELING ANTI-PSYCHOTIC ACTIVITY USING VIRTUAL SCREENING MODEL | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-18 | — | — | US | disclosed |
| US-20130184462-A1 | METHOD FOR PREDICTING AND MODELING ANTI-PSYCHOTIC ACTIVITY USING VIRTUAL SCREENING MODEL | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-18 | — | — | US | disclosed |
| CN-101607923-B | Aromatic nitrile compounds or derivatives of same and synthetic method and application thereof | JIAO NING | 2012-12-19 | — | — | CN | disclosed |
| US-7994331-B2 | Heterocycle-substituted benzimidazole derivative | MSD K.K. (JP) | 2011-08-09 | — | — | US | disclosed |
| CN-101094847-B | Aryloxy-substituted benzimidazole derivatives | BANYU PHARMA CO LTD | 2011-06-15 | — | — | CN | disclosed |
| US-7932394-B2 | 1-{[5-[4-(Methylsulfonyl)phenoxy]-2-(2-pyridinyl)-1H-benzimidazol-6-yl]methyl}-5-thioxo-2-pyrrolidinone;glucokinase activator; antidiabetic agents; obesity; prevention of retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis; antiischemic agents; cardiotonic agents | MSD K.K. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20100087360-A1 | Heterocycle-substituted benzimidazole derivative | MSD K.K. (JP) | 2010-04-08 | — | — | US | disclosed |
| CN-101607923-A | Aromatic nitrile compounds or derivatives thereof and synthetic method thereof and application | NING JIAO (CN) | 2009-12-23 | — | — | CN | disclosed |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1905769-A1 | HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-02 | — | — | EP | disclosed |
| CN-101094847-A | Aryloxy-substituted benzimidazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1810969-A1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087360-A1 | Heterocycle-substituted benzimidazole derivative | GCK, GCKR, HK1 | MAOB 2345/4885ALDH1A1 1946/4885MAPT 4648/4885 |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | GCK, GCKR, SLC5A1 | MAOB 1422/4885ALDH1A1 1126/4885MAPT 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.